NASDAQ:GMDAGamida Cell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gamida Cell Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.29 +0.14 (+3.37 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$4.15Now: $4.29▼$4.3750-Day Range$3.93MA: $4.38▼$4.9952-Week Range$2.60Now: $4.29▼$7.70Volume200,240 shsAverage Volume208,436 shsMarket Capitalization$103.90 millionP/E RatioN/ADividend YieldN/ABeta1.95 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGamida Cell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Gamida Cell has a potential upside of 280.7% from its current price of $4.29.Amount of Analyst CoverageGamida Cell has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesGamida Cell has received 75 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGamida Cell has received 69 “underperform” votes. (Add your “underperform” vote.)Community SentimentGamida Cell has received 52.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Gamida Cell and other stocks. Vote “Outperform” if you believe GMDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GMDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGamida Cell does not currently pay a dividend.Dividend GrowthGamida Cell does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gamida Cell insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 21.76% of the stock of Gamida Cell is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gamida Cell are expected to grow in the coming year, from ($1.11) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gamida Cell is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gamida Cell is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGamida Cell has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMDA Previous Symbol CUSIPN/A CIKN/A Webwww.gamida-cell.com Phone972-2659-5666Debt Debt-to-Equity Ratio0.19 Current Ratio4.15 Quick Ratio4.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book2.98Profitability EPS (Most Recent Fiscal Year)($1.69) Net Income$-34,350,000.00 Net MarginsN/A Return on Equity-138.59% Return on Assets-69.45%Miscellaneous Employees79 Outstanding Shares24,220,000Market Cap$103.90 million Next Earnings Date8/11/2020 (Confirmed) OptionableNot Optionable $4.29 +0.14 (+3.37 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GMDA News and Ratings via Email Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter. Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions How has Gamida Cell's stock been impacted by COVID-19 (Coronavirus)? Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GMDA stock has increased by 1.4% and is now trading at $4.29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Gamida Cell? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gamida Cell. When is Gamida Cell's next earnings date? Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Gamida Cell. How were Gamida Cell's earnings last quarter? Gamida Cell Ltd (NASDAQ:GMDA) posted its quarterly earnings data on Thursday, May, 21st. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.12. View Gamida Cell's earnings history. What price target have analysts set for GMDA? 7 Wall Street analysts have issued 1-year price objectives for Gamida Cell's stock. Their forecasts range from $13.00 to $20.00. On average, they anticipate Gamida Cell's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 280.7% from the stock's current price. View analysts' price targets for Gamida Cell. Has Gamida Cell been receiving favorable news coverage? News coverage about GMDA stock has been trending positive recently, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gamida Cell earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about Gamida Cell. Are investors shorting Gamida Cell? Gamida Cell saw a increase in short interest in July. As of July 15th, there was short interest totaling 53,800 shares, an increase of 198.9% from the June 30th total of 18,000 shares. Based on an average daily volume of 388,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the company's shares are sold short. View Gamida Cell's Short Interest. Who are some of Gamida Cell's key competitors? Some companies that are related to Gamida Cell include PDL BioPharma (PDLI), Precision BioSciences (DTIL), Eiger Biopharmaceuticals (EIGR), Harpoon Therapeutics (HARP), Cabaletta Bio (CABA), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA), DBV TECHNOLOGIE/S (DBVT), Dyadic International (DYAI), Pluristem Therapeutics (PSTI), CASI Pharmaceuticals (CASI), Fennec Pharmaceuticals (FENC), Sutro Biopharma (STRO), GENFIT S A/ADR (GNFT) and Axcella Health (AXLA). View all competitors. What other stocks do shareholders of Gamida Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Pennsylvania R.E.I.T. (PEI), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX) and KushCo (KSHB). Who are Gamida Cell's key executives? Gamida Cell's management team includes the following people: Dr. Julian Adams Ph.D., CEO & Director (Age 65, Pay $740k)Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 44, Pay $353k)Dr. Ronit Simantov, Chief Medical Officer (Age 55, Pay $587k)Mr. Joshua D. Hamermesh MBA, Chief Bus. Officer (Age 48, Pay $508k)Mr. Thomas J. Klima, Chief Commercial Officer (Age 48, Pay $392k) When did Gamida Cell IPO? (GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager. What is Gamida Cell's stock symbol? Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA." Who are Gamida Cell's major shareholders? Gamida Cell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.91%), Phoenix Holdings Ltd. (0.24%) and Edmond DE Rothschild Holding S.A. (0.03%). Which major investors are selling Gamida Cell stock? GMDA stock was sold by a variety of institutional investors in the last quarter, including Edmond DE Rothschild Holding S.A.. Which major investors are buying Gamida Cell stock? GMDA stock was bought by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., and Phoenix Holdings Ltd.. How do I buy shares of Gamida Cell? Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gamida Cell's stock price today? One share of GMDA stock can currently be purchased for approximately $4.29. How big of a company is Gamida Cell? Gamida Cell has a market capitalization of $103.90 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Gamida Cell employs 79 workers across the globe. What is Gamida Cell's official website? The official website for Gamida Cell is www.gamida-cell.com. How can I contact Gamida Cell? Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
